Nurse-Led Vital Signs Monitoring Can Safely Identify Low-Risk Hematology-Oncology Patients For De-Escalation.

PURPOSE: It is routine practice for patients to be on vital signs monitoring (VSM) once every 4 hours, which is laborious and disruptive. VSM de-escalation has been demonstrated to be safe in low-risk (LR) patients, but it has not been well studied in the hematology-oncology setting. METHODS: A quality improvement project was conducted in 3 hematology-oncology inpatient wards within a comprehensive cancer center, from March 2017 to July 2017 (pilot phase) and from October 2017 to Sept 2018 (maintenance phase). Root causes for frequent VSM identified via problem analysis include (1) perception of VSM, (2) lack of concise clinical guidelines, and (3) lack of nurse empowerment. Consensus criteria to define suitable LR patients and a nurse-led VSM de-escalation protocol were formulated. RESULTS: Of 1,065 patients who underwent nurse-led VSM de-escalation, there was a 50% reduction in the mean number of nurse encounters (NE) per month (P < .01), with total savings of 2,731.5 NE-minutes per month. VSM re-escalation was required by 10.1% of patients; all were deemed unpreventable with more frequent VSM and none resulted in severe adverse outcomes. With additional interventions such as spot audits and retraining, recruitment for de-escalation improved from 51.7% of LR admissions in the pilot phase to 93.8% in the maintenance phase (P < .01). The time saved was used to enhance other aspects of patient care, such as patient education. One hundred thirty-nine of 169 doctors and nurses surveyed after implementation (96.5%) supported continuing this protocol. CONCLUSION: A well-defined protocol allows safe nurse-led de-escalation of VSM for LR patients without adverse outcomes and was shown to be sustainable in this cohort of hematology-oncology patients.

Antegrade repositioning of Memokath stent in malignant ureteroileal anastomotic stricture.

Ureteric strictures are common and can be due to benign or malignant causes. Various surgical treatments can be used from minimally invasive endoscopic retrograde JJ stent insertion, balloon dilatation, ureterolithotomy, to open surgical exploration and repair. Memokath 051 stent is a metallic stent designed for long-term ureteral stenting in the management of ureteral strictures. The insertion of this device is usually a straightforward procedure performed endoscopically in a retrograde fashion via cystoscopy. However, this procedure can be difficult in complicated scenarios when the bladder has been removed with neoureteral reimplantations or high-grade strictures. Here, we report a case of Memokath stent insertion complicated by placement difficulties in a lady with ileal conduit due to previous ovarian cancer complicated by vesicovaginal fistula, who presented with malignant stricture of the ureteroileal anastomosis. We describe a simple yet effective antegrade technique to precisely reposition the malpositioned Memokath stent, along with illustrations.

Evaluation of bowel distension and mural visualisation using neutral oral contrast agents for multidetector-row computed tomography.

INTRODUCTION: We compared the effectiveness of different types of non-commercial neutral oral contrast agents for bowel distension and mural visualisation in computed tomographic (CT) enterography. METHODS: 90 consecutive patients from a group of 108 were randomly assigned to receive water (n = 30), 3.8% milk (n = 30) or 0.1% gastrografin (n = 30) as oral contrast agent. The results were independently reviewed by two radiologists who were blinded to the contrast agents used. The degree of bowel distension was qualitatively scored on a four-point scale. The discrimination of bowel loops, mural visualisation and visualisation of mucosal folds were evaluated on a 'yes' or 'no' basis. Side effects of the various agents were also recorded. RESULTS: 3.8% milk was significantly superior to water for bowel distension (jejunum, ileum and terminal ileum), discrimination of bowel loops (jejunum and ileum), mural visualisation and visualisation of mucosal folds (ileum and terminal ileum). It was also significantly superior to 0.1% gastrografin for bowel distension, discrimination of bowel loops, mural visualisation and visualisation of mucosal folds (jejunum, ileum and terminal ileum). However, 10% of patients who received 3.8% milk reported immediate post-test diarrhoea. No side effects were documented for patients who received water and 0.1% gastrografin. CONCLUSION: 3.8% milk is an effective and superior neutral oral contrast agent for the assessment of the jejunum, ileum and terminal ileum in CT enterography. However, further studies are needed to explore other suitable oral contrast agents for CT enterography in lactose- or cow's milk-intolerant patients.